Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Vivo Capital Closes $100 Million Fund for Early-Stage US-China Healthcare Companies

publication date: Jun 14, 2016
Vivo Capital, a California-China healthcare investment firm, has closed an early stage healthcare VC fund, the Vivo PANDA Fund with more than $100 million. Traditionally, Vivo has looked for later-stage investments. In 2015, Vivo closed its $750 million eighth fund, which focused on China revenue-stage life science companies. The new fund will invest in innovative healthcare companies, including pharmaceuticals, biotechnology, medical devices and diagnostics, with an eye toward building cross-border partnerships. Vivo now manages over $1.8 billion. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital